Human Immunology Biosciences
Human Immunology Biosciences Employees
13 people indexed:
-
8up0g40@5lu8y.qf1 Sign up to see email
-
David Schisla
Vice President, Chemistry Manufacturing and Controls
w6nfr232@6nz9t.rqp Sign up to see email78tw13e8@pfe9r.91e Sign up to see email -
Donna Flesher
Vice President, Biomarker and Bioanalytical Sciences
a486t5kv@3uq3n.jy0 Sign up to see email71qt4wyg@j9qjp.88k Sign up to see email -
9kd14dd1w4q@sf321.yqf Sign up to see email
-
0uq6d513@01k62.2vd Sign up to see email
-
p2ttp87@175gq.rwy Sign up to see email
-
w9w966r@pe0lv.kvs Sign up to see email
-
2a4utg@er03w.rq7 Sign up to see email
-
pppszq@14ert.jdy Sign up to see email
-
qquy9ukg0@0dzwj.wqy Sign up to see email
-
f6qj47nq@ya7kf.4yl Sign up to see email
-
Tyler Chavez
Senior Director, Alliance Management & Corporate Development
lp0u34p@91g3x.8fn Sign up to see email9gdnwsu@x8k66.w85 Sign up to see email -
9xq5fx@6dxnx.2qk Sign up to see email
Human Immunology Biosciences Company Information
Human Immunology Biosciences is a biotechnology company located at 6000 Shoreline Court, Suite 304, South San Francisco, CA 94080. The company specializes in leveraging human genetic and immunological insights to develop targeted therapies for severe immune-mediated diseases. It has several clinical-stage programs and a robust pipeline addressing a range of diseases across the immune landscape. Human Immunology Biosciences recently announced a $95 million Series B financing to further advance these therapies. The company has received FDA Orphan Drug Designation for Felzartamab for the treatment of Antibody-Mediated Rejection in kidney transplant recipients and Breakthrough Therapy Designation for the treatment of Primary Membranous Nephropathy. It holds exclusive worldwide rights to Felzartamab, excluding Greater China. Additionally, the company is developing Izastobart/HIB210, an anti-C5aR1 antibody aimed at treating complement-mediated diseases, holding exclusive rights worldwide except in Greater China and South Korea.
No searches found for this company.